LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Elenco Azioni・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Chiusa

SettoreSettore sanitario

20.89 -0.24

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

20.21

Massimo

21.43

Metriche Chiave
By Trading Economics
Entrata	-14M -50M
Vendite	12M 128M
Margine di Profitto	-39.506
Dipendenti	1,784
EBITDA	-17M -48M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+66.21% upside

Dividendi
By Dow Jones
Utili prossimi	7 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	174M 2.4B
Apertura precedente	21.13
Chiusura precedente	20.89

Notizie sul Sentiment di mercato

By Acuity

43%

57%

165 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

28.13 / 31.12 Supporto e resistenza

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 mag 2026, 23:41 UTC

Utili

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 mag 2026, 21:40 UTC

Utili

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 mag 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 mag 2026, 23:34 UTC

Discorsi di Mercato

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 mag 2026, 23:13 UTC

Utili

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 mag 2026, 23:13 UTC

Utili

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 mag 2026, 23:12 UTC

Utili

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 mag 2026, 23:11 UTC

Utili

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 mag 2026, 23:07 UTC

Utili

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 mag 2026, 23:06 UTC

Utili

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 mag 2026, 23:06 UTC

Utili

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 mag 2026, 23:05 UTC

Utili

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 mag 2026, 23:04 UTC

Utili

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 mag 2026, 22:50 UTC

Utili

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 mag 2026, 22:25 UTC

Discorsi di Mercato

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 mag 2026, 22:11 UTC

Utili

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 mag 2026, 22:11 UTC

Utili

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 mag 2026, 22:05 UTC

Discorsi di Mercato

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 mag 2026, 21:58 UTC

Utili

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mag 2026, 21:47 UTC

Discorsi di Mercato

Utili

Costco Posts 13% Sales Growth in April -- Market Talk

6 mag 2026, 21:46 UTC

Utili

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 mag 2026, 21:40 UTC

Utili

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mag 2026, 21:35 UTC

Discorsi di Mercato

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 mag 2026, 21:32 UTC

Azioni calde

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 mag 2026, 21:29 UTC

Utili

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

66.21% in crescita

Previsioni per 12 mesi

Media 35.27 USD 66.21%

Alto 47 USD

Basso 21.8 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 4 che hanno fornito valutazioni azionarie a Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

28.13 / 31.12Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

165 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.